Category Archives : News

Home  >>  News

VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

On December 14, 2018, Posted by , In News, By , With Comments Off on VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the first patient has been dosed in a Phase I/II trial evaluating VXM01 oral immunotherapy in combination with avelumab*, a human anti-PD-L1 antibody, for the treatment of glioblastoma. The trial is part of a collaboration…

DKFZ/EMBL: Computer model to predict prostate cancer progress

On December 11, 2018, Posted by , In News, By , With Comments Off on DKFZ/EMBL: Computer model to predict prostate cancer progress

  IMAGE: Colourbox – Kiyoshi Takahase Segundo Cancer researchers have developed a computer model that can predict the course of disease for prostate cancer, based on cancer patient genomic and clinical data The model is currently being implemented at a prostate cancer clinic in Germany. The researchers have also found…

Baden-Württemberg awarded two research prizes to Heidelberg

On December 11, 2018, Posted by , In News, By , With Comments Off on Baden-Württemberg awarded two research prizes to Heidelberg

This year, the Landesforschungspreis Baden-Württemberg for excellence in applied research goes to Andreas Trumpp from the German Cancer Research Centre (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH). Theresia Bauer, Minister of Science, Research and the Arts, presented the 100,000 euro award at a…

Leibniz Prize for Hans-Reimer Rodewald (DKFZ)

On December 10, 2018, Posted by , In News, By , With Comments Off on Leibniz Prize for Hans-Reimer Rodewald (DKFZ)

Hans-Reimer Rodewald of the German Cancer Research Center receives the Gottfried Wilhelm Leibniz Prize 2019, the most important research award in Germany. Rodewald’s research revolves around the question of how the different types of immune cells develop from stem cells and together form a functional defence system. Hans-Reimer Rodewald ©…

Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

On December 10, 2018, Posted by , In News, By , With Comments Off on Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

Data Confirm Clinical Single-Agent Activity of AFM13 in CD30-Positive Lymphoma with Cutaneous Presentation and Doubled Complete Response Rate of AFM13 in Combination with Keytruda® (Pembrolizumab) in Hodgkin Lymphoma Patients Future Combination Opportunities Include Combination of CD16A Immune Cell Engagers with Adoptive NK Cell Transfer Heidelberg, Germany, December 3, 2018 –…

DKFZ/EMBL: New Ways to Look at Protein-RNA Networks

On December 10, 2018, Posted by , In News, By , , With Comments Off on DKFZ/EMBL: New Ways to Look at Protein-RNA Networks

For their vital tasks, all RNA molecules in our cells require proteins as binding partners. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and colleagues from the European Molecular Biology Laboratory (EMBL) have developed the first method with which they can analyze the composition of the entire RNA-protein…

Solmic Research GmbH and the European Molecular Biology Laboratory enter into a research collaboration

On December 3, 2018, Posted by , In News, By , With Comments Off on Solmic Research GmbH and the European Molecular Biology Laboratory enter into a research collaboration

Solmic Research GmbH has entered into a research collaboration with the European Molecular Biology Laboratory (EMBL) with the goal to elucidate the mode of action of natural extracts. Natural extracts, such as active ingredients of plants, are the origin of medicine and are widely used for medical applications, especially in…

DKFZ/EMBL: Algorithm identifies multiple gene–environment relationships

On November 30, 2018, Posted by , In News, By , , With Comments Off on DKFZ/EMBL: Algorithm identifies multiple gene–environment relationships

Researchers at the German Cancer Research Center (DKFZ), EMBL’s European Bioinformatics Institute (EMBL-EBI) and the Wellcome Sanger Institute have developed a new computational method that makes it possible to identify the impact of hundreds of environmental factors on genotype–environment interactions. The method will enhance understanding of relationship between genotype and…

DKFZ: Defective DNA damage repair leads to chaos in the genome

On November 14, 2018, Posted by , In News, By , , With Comments Off on DKFZ: Defective DNA damage repair leads to chaos in the genome

Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now found a cause for the frequent catastrophic events in the genetic material of cancer cells that have only been known for a few years: If an important DNA repair system of the cells has failed, this promotes fragmentation…

A faster lane towards effective therapies of childhood brain cancer

On November 6, 2018, Posted by , In News, By ,, , With Comments Off on A faster lane towards effective therapies of childhood brain cancer

Scientists of the „Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ), the German Cancer Consortium (DKTK) and the German Cancer Research Center (DKFZ), in collaboration with colleagues from Seattle, U.S.A., have built a collection of tumor models that can be used to test anticancer drugs for treating childhood brain…